DK156660C - Analogifremgangsmaade til fremstilling af imidazolylthien-2-yl eller imidazolylalkylthien-2-yl-tetrahydro-pyridaziner eller farmaceutisk acceptable salte deraf - Google Patents

Analogifremgangsmaade til fremstilling af imidazolylthien-2-yl eller imidazolylalkylthien-2-yl-tetrahydro-pyridaziner eller farmaceutisk acceptable salte deraf

Info

Publication number
DK156660C
DK156660C DK505983A DK505983A DK156660C DK 156660 C DK156660 C DK 156660C DK 505983 A DK505983 A DK 505983A DK 505983 A DK505983 A DK 505983A DK 156660 C DK156660 C DK 156660C
Authority
DK
Denmark
Prior art keywords
imidazolylthien
imidazolylalkylthien
analogue
preparation
acceptable salts
Prior art date
Application number
DK505983A
Other languages
Danish (da)
English (en)
Other versions
DK505983A (da
DK505983D0 (da
DK156660B (da
Inventor
Gerd Hilboll
Gerrit Prop
Harald Borbe
Josef Peter Loehr
Elisabeth-Stephanie Doppelfeld
Original Assignee
Nattermann A & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattermann A & Cie filed Critical Nattermann A & Cie
Publication of DK505983D0 publication Critical patent/DK505983D0/da
Publication of DK505983A publication Critical patent/DK505983A/da
Publication of DK156660B publication Critical patent/DK156660B/da
Application granted granted Critical
Publication of DK156660C publication Critical patent/DK156660C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK505983A 1982-11-06 1983-11-04 Analogifremgangsmaade til fremstilling af imidazolylthien-2-yl eller imidazolylalkylthien-2-yl-tetrahydro-pyridaziner eller farmaceutisk acceptable salte deraf DK156660C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3241102 1982-11-06
DE19823241102 DE3241102A1 (de) 1982-11-06 1982-11-06 Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung

Publications (4)

Publication Number Publication Date
DK505983D0 DK505983D0 (da) 1983-11-04
DK505983A DK505983A (da) 1984-05-07
DK156660B DK156660B (da) 1989-09-18
DK156660C true DK156660C (da) 1990-03-05

Family

ID=6177509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK505983A DK156660C (da) 1982-11-06 1983-11-04 Analogifremgangsmaade til fremstilling af imidazolylthien-2-yl eller imidazolylalkylthien-2-yl-tetrahydro-pyridaziner eller farmaceutisk acceptable salte deraf

Country Status (11)

Country Link
US (1) US4643998A (fr)
EP (1) EP0112987B1 (fr)
JP (1) JPS59108781A (fr)
AT (1) ATE26274T1 (fr)
DE (2) DE3241102A1 (fr)
DK (1) DK156660C (fr)
ES (1) ES8406472A1 (fr)
GR (1) GR78945B (fr)
IE (1) IE56127B1 (fr)
PT (1) PT77616B (fr)
ZA (1) ZA837976B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407509A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Neue arzneimittelkombination zur behandlung von bluthochdruck und thromboembolischen erkrankungen
DE3606105A1 (de) * 1986-02-26 1987-08-27 Nattermann A & Cie Verfahren zur herstellung von imidazolyl-thiophenaldehyden
DE3626865A1 (de) * 1986-08-08 1988-02-11 Boehringer Mannheim Gmbh Neue pyridazinon-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004036075B3 (de) * 2004-07-24 2006-02-16 Bos Gmbh & Co. Kg Anordnung für Seitenfensterrollo
EP2218442A1 (fr) 2005-11-09 2010-08-18 CombinatoRx, Inc. Procédés, compositions et kits pour le traitement des maladies ophthalmiques
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
CN106065012A (zh) * 2015-04-24 2016-11-02 广东众生药业股份有限公司 咪唑类化合物
MA44674B1 (fr) 2016-04-15 2020-06-30 Abbvie Inc Inhibiteurs de bromodomaine
WO2018072702A1 (fr) * 2016-10-20 2018-04-26 南京明德新药研发股份有限公司 Forme cristalline de composé imidazole, type de sel et son procédé de préparation
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130252A1 (de) * 1981-07-31 1983-02-17 A. Nattermann & Cie GmbH, 5000 Köln 6-(5-((omega)-(1-imidazolyl)-alkyl)-thien-2-yl)-3-oxo-2,3,4,5-tetrahydro-pyridazine und deren saeureadditionssalze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
HU190412B (en) * 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) * 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones

Also Published As

Publication number Publication date
IE832484L (en) 1984-05-06
EP0112987B1 (fr) 1987-04-01
ZA837976B (en) 1984-06-27
DK505983A (da) 1984-05-07
DK505983D0 (da) 1983-11-04
US4643998A (en) 1987-02-17
ES527027A0 (es) 1984-07-01
ES8406472A1 (es) 1984-07-01
DK156660B (da) 1989-09-18
PT77616A (en) 1983-12-01
ATE26274T1 (de) 1987-04-15
JPH054391B2 (fr) 1993-01-19
EP0112987A1 (fr) 1984-07-11
GR78945B (fr) 1984-10-02
JPS59108781A (ja) 1984-06-23
PT77616B (en) 1986-03-19
DE3370626D1 (en) 1987-05-07
IE56127B1 (en) 1991-04-24
DE3241102A1 (de) 1984-05-10

Similar Documents

Publication Publication Date Title
DK156660C (da) Analogifremgangsmaade til fremstilling af imidazolylthien-2-yl eller imidazolylalkylthien-2-yl-tetrahydro-pyridaziner eller farmaceutisk acceptable salte deraf
DK153399C (da) Analogifremgangsmaade til fremstilling af 2,4-diaminoquinazolin-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf og 4-aminoquinazolin-forbindelser til anvendelse som udgangsmateriale ved fremgangsmaaden
DK145339C (da) Analogifremgangsmaade til fremstilling af 4-amino-5-hexensyre eller farmaceutisk acceptable salte deraf
DK164545C (da) Analogifremgangsmaade til fremstilling af sulfonylamino- eller sulfonylaminoalkylphenoxyalkylcarbonsyrederivater eller fysiologisk uskadelige salte deraf
DK151010C (da) Analogifremgangsmaade til fremstilling af n-(substitueret aminoalkyl)-2-oxo-1-pyrrolidinacetamider eller farmaceutisk acceptable syreadditionssalte deraf
NO832630L (no) Trifenylimidazolyloxyalkansyrer og deres derivater, deres fremstilling og deres anvendelse i preparater
DK151884C (da) Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK103384D0 (da) Quinoloncarboxylsyrer eller salte eller hydrater deraf, deres fremstilling og anvendelse som antibakterielle midler
NO820686L (no) Fremgangsmaate ved fremstilling av nye aroylimidazoloner
DK148183D0 (da) Fremgangsmade til fremstilling af imidazolylphenyl-tetrahydropyridaziner
DK161968C (da) Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf
DK151017C (da) Analogifremgangsmaade til fremstilling af substituerede n-(4-indolyl-piperidino-alkyl)-benzimidazoloner eller fysiologisk acceptable syreadditionssalte deraf
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
DK160942C (da) Fremgangsmaade til fremstilling af 7-(eventuelt substitueret amino)-3-(substitueret)thiomethyl-delta3-cephem-4-carboxylsyre-forbindelser eller derivater i carboxylgruppen deraf eller salte deraf
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK165005C (da) Analogifremgangsmaade til fremstilling af 4,5-dihydro-4-oxofuran-2-carboxylsyrederivater eller terapeutisk acceptable salte deraf
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
DK149590C (da) Analogifremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo(4,1,0)hepten-(2)-on-(5)-forbindelser
DK157021C (da) Analogifremgangsmaade til fremstilling af 2,3-polymethylen-4-oxo-4h-pyrido- eller -azepinooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf
DK156068C (da) Analogifremgangsmaade til fremstilling af n-(2-methoxyethyl)-noroxymorphon eller syreadditionssalte deraf
DK150481C (da) Analogifremgangsmaade til fremstilling af 3',4'-dihydro-spiro-(imidazolidin-4,1'-(2'h)-naphthalen)-5-on eller farmaceutisk acceptable syreadditionssalte deraf
DK160874C (da) Analogifremgangsmaade til fremstilling af ergol-8-en- eller ergolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK320081A (da) Fremgangsmaade til fremstilling af thiazolyl-2-oxamidsyrederivater
DK157686C (da) Analogifremgangsmaade til fremstilling af 7-beta-substituerede imidazolidinyl-3-chlor-3-cephem-4-carboxylsyrer eller farmaceutisk acceptable salte deraf
DK154217C (da) Analogifremgangsmaade til fremstilling af 3-azetidinylaetyl-1-fenyl-2-imidazolidinonderivater eller farmaceutisk acceptable syreadditionssalte deraf

Legal Events

Date Code Title Description
PBP Patent lapsed